BACKGROUND: Invasive aspergillosis (IA) continues to be a leading cause of morbidity and mortality in hematologic malignancy (HM) patients. We evaluated the prognostic factors for IA in HM patients. METHODS: In this retrospective study, we included all HM patients diagnosed with proven or probable IA between June 1993 and June 2008. RESULTS: A total of 449 HM patients were analyzed, the majority of which (75%) had underlying leukemia. Multivariate logistic regression analysis showed that neutropenia for more than two weeks during IA, steroid use, and intensive care admission were independently associated with failure to respond to antifungal therapy, as well as increased IA-attributable mortality (all p-values < .01). Antifungal therapy with an antimold azole-containing regimen (voriconazole or posaconazole) was also independently associated with improved response to treatment, as well as decreased IA-attributable mortality (all p-values < .0001). Survival analysis showed that primary or salvage therapy with a regimen that contained antimold azoles was significantly associated with improved survival (p < .001). CONCLUSIONS: In HM patients, persistent neutropenia and the need for intensive care are associated with failure to respond to antifungal therapy. Use of novel antimold azoles, either as primary or salvage therapy, improves the overall outcome and IA-attributable death of HM patients with IA.
BACKGROUND: Invasive aspergillosis (IA) continues to be a leading cause of morbidity and mortality in hematologic malignancy (HM) patients. We evaluated the prognostic factors for IA in HM patients. METHODS: In this retrospective study, we included all HM patients diagnosed with proven or probable IA between June 1993 and June 2008. RESULTS: A total of 449 HM patients were analyzed, the majority of which (75%) had underlying leukemia. Multivariate logistic regression analysis showed that neutropenia for more than two weeks during IA, steroid use, and intensive care admission were independently associated with failure to respond to antifungal therapy, as well as increased IA-attributable mortality (all p-values < .01). Antifungal therapy with an antimold azole-containing regimen (voriconazole or posaconazole) was also independently associated with improved response to treatment, as well as decreased IA-attributable mortality (all p-values < .0001). Survival analysis showed that primary or salvage therapy with a regimen that contained antimold azoles was significantly associated with improved survival (p < .001). CONCLUSIONS: In HM patients, persistent neutropenia and the need for intensive care are associated with failure to respond to antifungal therapy. Use of novel antimold azoles, either as primary or salvage therapy, improves the overall outcome and IA-attributable death of HM patients with IA.
Authors: W R Kirkpatrick; R K McAtee; A W Fothergill; D Loebenberg; M G Rinaldi; T F Patterson Journal: Antimicrob Agents Chemother Date: 2000-03 Impact factor: 5.191
Authors: S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh Journal: Clin Infect Dis Date: 2001-11-26 Impact factor: 9.079
Authors: P Ribaud; C Chastang; J P Latgé; L Baffroy-Lafitte; N Parquet; A Devergie; H Espérou; F Sélimi; V Rocha; H Espérou; F Sélimi; V Rocha; F Derouin; G Socié; E Gluckman Journal: Clin Infect Dis Date: 1999-02 Impact factor: 9.079
Authors: Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw Journal: N Engl J Med Date: 2002-08-08 Impact factor: 91.245
Authors: T J Walsh; J W Hiemenz; N L Seibel; J R Perfect; G Horwith; L Lee; J L Silber; M J DiNubile; A Reboli; E Bow; J Lister; E J Anaissie Journal: Clin Infect Dis Date: 1998-06 Impact factor: 9.079
Authors: I I Raad; A M Chaftari; M M Al Shuaibi; Y Jiang; W Shomali; J E Cortes; B Lichtiger; R Y Hachem Journal: Ann Oncol Date: 2013-03-21 Impact factor: 32.976
Authors: Margaret V Powers-Fletcher; Kalyani Jambunathan; Jordan L Brewer; Karthik Krishnan; Xizhi Feng; Amit K Galande; David S Askew Journal: PLoS One Date: 2011-12-07 Impact factor: 3.240